Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Is the COMS Worthwhile?-Reply

Is the COMS Worthwhile?-Reply Abstract In Reply. —Commenting on my editorial "Do I Take the Eye Out or Leave It In?" Dr Benson has raised a number of questions that are difficult to answer satisfactorily in a small space. The difficulty of providing quick answers becomes even more apparent when one considers that some of the best minds in ophthalmology, radiation oncology, epidemiology, biostatistics, and medical oncology have been struggling with some of these same questions for years. The issues raised are important, however, and I welcome the opportunity to address them. I believe that such dialogue is intellectually healthy for our specialty and that it can promote better patient care by enhancing the appreciation of how the randomized clinical trial can be used to assess new as well as standard therapies.Dr Benson begins by asserting that the COMS would be strong if certain experienced ophthalmologists had agreed to participate. These ophthalmologists were encouraged References 1. Augsburger JJ, Gamel JW, Sardi VF, et al: Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body . Arch Ophthalmol 1986;104:655-661.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Ophthalmology American Medical Association

Is the COMS Worthwhile?-Reply

Fine, Stuart L.
Archives of Ophthalmology , Volume 104 (12) – Dec 1, 1986
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/is-the-coms-worthwhile-reply-hzm2c0r4vP

References (1)

Publisher
American Medical Association
Copyright
Copyright © 1986 American Medical Association. All Rights Reserved.
ISSN
0003-9950
eISSN
1538-3687
DOI
10.1001/archopht.1986.01050240019005
Publisher site
See Article on Publisher Site

Abstract

Abstract In Reply. —Commenting on my editorial "Do I Take the Eye Out or Leave It In?" Dr Benson has raised a number of questions that are difficult to answer satisfactorily in a small space. The difficulty of providing quick answers becomes even more apparent when one considers that some of the best minds in ophthalmology, radiation oncology, epidemiology, biostatistics, and medical oncology have been struggling with some of these same questions for years. The issues raised are important, however, and I welcome the opportunity to address them. I believe that such dialogue is intellectually healthy for our specialty and that it can promote better patient care by enhancing the appreciation of how the randomized clinical trial can be used to assess new as well as standard therapies.Dr Benson begins by asserting that the COMS would be strong if certain experienced ophthalmologists had agreed to participate. These ophthalmologists were encouraged References 1. Augsburger JJ, Gamel JW, Sardi VF, et al: Enucleation vs cobalt plaque radiotherapy for malignant melanomas of the choroid and ciliary body . Arch Ophthalmol 1986;104:655-661.Crossref

Journal

Archives of Ophthalmology – American Medical Association

Published: Dec 1, 1986

There are no references for this article.